Last week, The US Food and Drug Administration (FDA) unveiled its
plan for advancing regulatory science, identifying eight priority areas
on which the agency will focus. The “Strategic Plan for Regulatory
Science,” builds on FDA’s report, “Advancing Regulatory Science for
Public Health,” released last year. “As new discoveries yield
increasingly complex products, this strategic plan ensures that our
experts are equipped to make science-based decisions resulting in sound
regulatory policy," said FDA Commissioner Margaret Hamburg. The priority
areas identified in the plan include supporting innovations in
personalized medicine and manufacturing, improved data sharing and
facilitating development of medical countermeasures to protect against
threats to public health. Senator Michael Bennet (D-CO) reacted to the
plan, asking FDA to go further by simplifying its review process and
making it more transparent and industry-friendly.
Read more: